Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 47, Issue 2, 2008, Pages 209-218

  Bangs, Mark E ^a   Tauscher Wisniewski, Sitra ^a   Polzer, John ^a   Zhang, Shuyu ^a   Acharya, Nayan ^a   Desaiah, Durisala ^a   Trzepacz, Paula T ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Suicidal behavior; Suicidal ideation

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA BASE; FOOD AND DRUG ADMINISTRATION; HUMAN; MANTEL HAENSZEL TEST; META ANALYSIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW;

EID: 38549087860     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/chi.0b013e31815d88b2     Document Type: Article

References (61)

1. Biederman J, Faraone SV. Current concepts on the neurobiology of attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl 1): S7-S16.
2. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215-1220.
3. Willcutt EG, Pennington BF, Chhabildas NA, et al. Psychiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins. J Am Acad Child Adolesc Psychiatry. 1999;38:1355-1362.
4. Houston K, Hawton K, Shepperd R. Suicide in young people aged 15Y24: a psychological autopsy study. J Affect Disord. 2001;63:159-170.
5. Brent D, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry. 1988;45:581-588.
6. Shaffi M, Steltz-Lenarsky J, Derrick AM, et al. Comorbidity of mental disorders in the post-mortem diagnosis of completed suicide in children and adolescents. J Affect Disord. 1988;15:227-233.
7. O'Donnell L, Stueve A, Wilson-Simmons R. Aggressive behaviors in early adolescence and subsequent suicidality among urban youths. J Adolesc Health. 2005;37:517.e15-517.e25.
8. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand. 2004;110:408-415.
9. Bymaster FP, Katner J, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
10. Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Pharmacother. 2003;4:1165-1174.
11. Swanson CJ, Perry KW, Koch-Krueger S, et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. 2006;50:755-760.
12. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941-1949.
13. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e1-e8.
14. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242-251.
15. Sevecke K, Battel S, Dittmann RW, et al. The effectiveness of atomoxetine in children, adolescents, and adults with ADHD: a systematic overview. Nervenarzt. 2006;773:294-308.
16. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry. 2004;161:757.
17. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother. 2005;39:1045-1048.
18. Stojanovski SD, Robinson RF, Baker SD, et al. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol. 2006;44:243-247.
19. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med. 2007;32:175-178.
20. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
21. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
22. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
23. Spencer TJ, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
24. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:647-655.
25. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
26. Posner K,Oquendo M,Stanley B, et al. Suicidality Classification Project. Food and Drug Administration Web site 2004. Available at: http://www.fda.gov/ ohrms/dockets/ac/04/slides/2004-4065S1_06_FDAPosner. ppt. Accessed March 5, 2007.
27. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41:55-68.
28. Sato T. On the variance estimator for the Mantel-Haenszel risk difference. Biometrics. 1989;45:1323-1324.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
30. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332-339.
31. Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry. 2006;63:246-248.
32. Posner K, Melvin GA, Stanley B, et al. Factors in the assessment of suicidality in youth. CNS Spectr. 2007;12:156-162.
33. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder - a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18:1119-1132.
34. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology. 2006;31:689-699.
35. Swensen A, Kruesi MJP, Allen AJ, et al. Self-injury and suicide in patients with attention-deficit/hyperactivity disorder. Presented at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 22-27, 2002.
36. Conners CK, Epstein JN, March JS, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry. 2001;40:159-167.
37. Barkley RA. Attention-Deficit/Hyperactivity Disorder: A Clinical Workbook. New York: Guilford; 1998.
38. Renaud J, Brent D, Birmaher B, et al. Suicide in adolescents with disruptive disorders. J Am Acad Child Adolesc Psychiatry. 1999;38:846-851.
39. Waxmonsky J. Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr. 2003;15:476-482.
40. O'Sullivan M, Fitzgerald M. Suicidal ideation and acts of self-harm among Dublin school children. J Adolesc. 1998;21:427-433.
41. Lynch F, Mills C, Daly I, et al. Challenging times: a study to detect Irish adolescents at risk of psychiatric disorders and suicidal ideation. J Adolesc. 2004;27:441-451.
42. Cowell JM, Gross D, McNaughton D, et al. Depression and suicidal ideation among Mexican American school-aged children. Res Theory Nurs Pract. 2005;19:77-94.
43. Fergusson DM, Lynskey MT. Suicide attempts and suicidal ideation in a birth cohort of 16-year-old New Zealanders. J Am Acad Child Adolesc Psychiatry. 1995;34:1308-1317.
44. Liu XC, Tein JY, Zhao ZT, et al. Suicidality and correlates among rural adolescents of China. J Adolesc Health. 2005;37:443-451.
45. Ryan ND. Treatment of depression in children and adolescents. Lancet. 2005;366:933-940.
46. Shaffer D, Pfeffer CR, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. J Am Acad Child Adolesc Psychiatry. 2001;40:24S-51S.
47. Thompson R, Briggs E, English DJ, et al. Suicidal ideation among 8-year-olds who are maltreated and at risk: findings from the LONG-SCAN studies. Child Maltreat. 2005;10:26-36.
48. Vinas F, Canals J, Gras ME, et al. Psychological and family factors associated with suicidal ideation in pre-adolescents. Span J Psychol. 2002;5:20-28.
49. van der Wal MF, de Wit CA, Hirasing RA. Psychosocial health among young victims and offenders of direct and indirect bullying. Pediatrics. 2003;111:1312-1317.
50. Cerel J, Roberts TA. Suicidal behavior in the family and adolescent risk behavior. J Adolesc Health. 2005;36:352.e9-352.e16.
51. Alaimo K, Olson CM, Frongillo EA. Family food insufficiency, but not low family income, is positively associated with dysthymia and suicide symptoms in adolescents. J Nutr. 2002;132:719-725.
52. Goodwin RD, Marusic A. Asthma and suicidal ideation among youth in the community. Crisis. 2004;25:99-102.
53. Haavisto A, Sourander A, Elilla H, et al. Suicidal ideation and suicide attempts among child and adolescent psychiatric inpatients in Finland. J Affect Disord. 2003;75:211-221.
54. Laor N, Wolmer L. Children exposed to disaster: the role of the mental health professional. In: Lewis M, ed. Child and Adolescent Psychiatry - A Comprehensive Textbook. Philadelphia: Lippincott Williams & Wilkins; 2002:925-937.
55. Weller E, Weller R, Benton T, et al. Grief. In: Lewis M, ed. Child and Adolescent Psychiatry - A Comprehensive Textbook. Philadelphia: Lippincott Williams & Wilkins; 2002:470-477.
56. Lewis M, Schonfeld D. Dying and death in childhood and adolescence. In: Lewis M, ed. Child and Adolescent Psychiatry - A Comprehensive Textbook. Philadelphia: Lippincott Williams & Wilkins; 2002:1239-1245.
57. Jacobsen LK, Rabinowitz I, Popper MS, et al. Interviewing prepubertal children about suicidal ideation and behavior. J Am Acad Child Adolesc Psychiatry. 1994;33:439-452.
58. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035-1043.
59. Greenhill LL, Vitiello B, Riddle MA, et al. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42:627-633.
60. Vitiello B, Riddle MA, Greenhill LL, et al. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry. 2003;42:634-641.
61. Carandang C, Santor D, Gardner DM, et al. Data safety monitoring boards and other study methodologies that address subject safety in "high-risk" therapeutic trials in youths. J Am Acad Child Adolesc Psychiatry. 2007;46:489-492.